Daliya Pencheva
Daliya received her PhD focused on systemic lupus erythematosus management from the Medical University of Sofia, Bulgaria. Her major interests are patient-reported outcome measures, quality of life and treat-to-target strategies. Daliya is a member of the Country Liaison Sub-committee.
| Poster 0050 | Wednesday 12.06.24 16:12 PM Clinical Poster Tours: Spondyloarthritis I Author:Van den Bosch, F (Belgium) Title: Efficacy and Safety of Upadacitinib in Patients with Active Non-radiographic Axial Spondyloarthritis: 2-Year Data from the Phase 3 SELECT-AXIS 2 Study  The 2-year SELECT-AXIS 2 trial assessed UPA 15 mg daily in nr-axSpA, showing sustained efficacy and no new safety signals. |
| Oral 0031 | Wednesday 12.06.24 16:40 PM Treating clinical aspects of SpA and PsA Author: Tskhakaia, I (USA) Title: Comparative Analysis of Tumor Necrosis Factor Alpha Inhibitors and Interleukin 17 Inhibitors in Psoriatic Arthritis: Exploring Cardiovascular Outcomes The study showed higher risks of heart failure and ischemic heart disease with TNFi therapy compared to IL-17i. |
| Oral 0195| Thursday 13.06.24 11:40 AM SpA & PsA – Treatment effects and response prediction Author: Mc Innes, I (UK) Title: Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody®, in patients with active psoriatic arthritis (PsA): Results from the global, randomized, double-blind, placebo-controlled Phase 2 ARGO Sonelokimab, a novel Nanobody targeting IL-17A and IL-17F, showed a rapid, robust clinical response and a favourable benefit–risk profile in the 12-week ARGO Phase 2 trial for active PsA. |
| Poster 0231 | Thursday 13.06.24 15:27 PM Treatment of Spondyloarthritis Author: Zhao, S (UK) Title: Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease, venous thromboembolism and cancer in psoriatic arthritis and axial spondyloarthritis Safety profile evaluation of JAKi in SpA, predominantly PsA, found no increased risk of cardiovascular disease, venous thromboembolism, or selected cancers compared to TNFi or IL-17i. |
| Poster 0259 | Friday 14.06.24 09:54 AM Clinical aspects of psoriatic arthritis Author: Ciurea, A (Switzerland) Title: Does biologic DMARD retention in axial psoriatic arthritis depend on the mode of action? Comparison of TNF, IL-17, and IL-23 inhibitors in a large observation cohort Drug retention rates in axPsA among TNFi, IL-17i, and IL-23i showed no significant difference in post-hoc analyses. |
| Poster 0266 | Friday 14.06.24 10:00 AM Clinical aspects of psoriatic arthritis Author: Parisi, S (Italy) Title: Cycling vs swap TNFi and IL17i in Psoriatic Arthritis: results from the BIRRA retrospective observational study The swap strategy (i.e. from TNFi to IL17i) proved to be the optimal strategy for PsA patients failing initial advanced treatment. |
| Oral 0003 | Saturday 15.06.24 09:10 AM Late-Breaking Abstracts Author: Baraliakos, X (Germany) Title: Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis Over 2 Years of Bimekizumab Treatment: Results From a Phase 3 Open-Label Extension Study BE MOBILE 2 study assessed Bimekizumab’s impact on 2-year radiographic progression in the spine of r-axSpA. |